Focusing on the GUCY2C Receptor: From Intestinal Physiology to Colorectal Cancer Immunotherapy Targets and Tool Protein Applications
Author: Senior Product Manager of UA Views：23 
This article systematically elaborates on the molecular characteristics and biological functions of GUCY2C, focusing on its physiological role as a member of the receptor guanylate cyclase family in maintaining intestinal homeostasis and regulating cGMP signaling. It also analyzes its early silencing mechanism in colorectal carcinogenesis and the abnormal overexpression features in metastatic colorectal cancer cells.
- Recent Advances
- Product Information
Recent Advances
Focus on GUCY2C Receptor: From Intestinal Physiology to Colorectal Cancer Immunotherapy Targets and Tool Protein Applications
Overview
This article systematically elaborates on the molecular characteristics and biological functions of GUCY2C as a member of the receptor guanylate cyclase family, highlighting its physiological role in maintaining intestinal homeostasis and regulating cGMP signaling. It also analyzes its early silencing mechanism in colorectal cancer development and its abnormal overexpression in metastatic colorectal cancer cells.
This article systematically elaborates on the molecular characteristics and biological functions of GUCY2C as a member of the receptor guanylate cyclase family, highlighting its physiological role in maintaining intestinal homeostasis and regulating cGMP signaling. It also analyzes its early silencing mechanism in colorectal cancer development and its abnormal overexpression in metastatic colorectal cancer cells.
I. Molecular Structure and Gene Localization of GUCY2C
Guanylate cyclase C (GUCY2C), also known as GC-C or STa receptor (STaR), belongs to the receptor guanylate cyclase family. In humans, it is encoded by the GUCY2C gene located on chromosome 12q12. GUCY2C serves as the intestinal receptor for bacterial heat-stable enterotoxins. It is a type I transmembrane glycoprotein with a molecular weight of approximately 120 kDa, consisting of five well-defined functional domains.
The extracellular N-terminal receptor-binding domain accounts for about 40% of the full-length protein and is responsible for specifically recognizing and binding its endogenous ligands (guanylin and uroguanylin) as well as bacterial heat-stable enterotoxins. The hydrophobic transmembrane domain forms a single-pass transmembrane helix structure, transmitting extracellular ligand-binding signals to the intracellular space. The cytoplasmic kinase homology domain acts as a relay module, transferring signals from the ligand-binding domain to the catalytic domain. The catalytic domain is the effector core of the protein, catalyzing the conversion of GTP to cGMP. The carboxyl terminus participates in protein stability regulation and interaction networks.
II. Physiological Functions of the GUCY2C-cGMP Signaling Axis
Upon activation, GUCY2C catalyzes the conversion of GTP to cGMP, which acts as a second messenger molecule to regulate downstream signaling pathways and perform various physiological functions in the intestine. In terms of intestinal fluid balance, cGMP activates protein kinase G and the cystic fibrosis transmembrane conductance regulator, modulating ion channel activity in intestinal epithelial cells. Regarding intestinal barrier function, GUCY2C signaling enhances epithelial barrier integrity by regulating the expression and distribution of tight junction proteins. In anti-inflammatory activity, the GUCY2C-cGMP pathway inhibits NF-κB activation and reduces the expression of pro-inflammatory factors.
III. Molecular Mechanisms of GUCY2C in Colorectal Cancer Development
The loss of GUCY2C ligands (i.e., silencing of receptor signaling) is a very common early step in colorectal cancer development, leading to genomic instability, metabolic reprogramming, and uncontrolled proliferation. The loss of endogenous GUCY2C-activating ligands occurs early in transformation and in chronic inflammatory epithelial cells, suggesting a mechanistic basis for colorectal cancer risk factors.
IV. Biomarker Value of GUCY2C in Metastatic Colorectal Cancer
GUCY2C is abnormally overexpressed in the tumor tissues of colorectal cancer patients, particularly in metastatic cancer cells. It shows strong positive expression in the peripheral blood of colorectal cancer patients, suggesting its potential as an early detection marker for postoperative recurrence and metastasis or as a specific molecular marker for metastatic colorectal cancer.
V. Potential of GUCY2C as an Immunotherapy Target
The expression characteristics of GUCY2C in metastatic cancer cells provide a target basis for various immunotherapy strategies. In CAR-T cell therapy, GUCY2C-targeting CAR-T cells have demonstrated specific cytotoxicity against colorectal cancer cells in preclinical and early clinical studies. In vaccine strategies, GUCY2C can serve as an antigen to induce specific T-cell immune responses. For immunotoxins, GUCY2C-targeting immunotoxins enable precise killing of GUCY2C-positive tumor cells.
VI. Conclusion
As a member of the intestine-specific receptor guanylate cyclase family, GUCY2C plays an irreplaceable physiological role in maintaining intestinal homeostasis. The silencing of its ligand signaling is a key molecular event in the early stages of colorectal cancer development. The abnormal overexpression of GUCY2C in metastatic colorectal cancer makes it a highly tumor-selective biomarker and therapeutic target. PE-labeled GUCY2C recombinant protein provides a reliable detection tool for foundational research and drug development in GUCY2C-targeted immunotherapy.
In the development of GUCY2C-targeted therapies and related research, high-quality fluorescent-labeled recombinant proteins are key tools for flow cytometry detection and target validation. To meet this research demand, Uni offers PE-Labeled GUCY2C Fc&Avi Tag Protein, Human, suitable for applications such as GUCY2C CAR-T cell positivity rate detection, binding activity evaluation of GUCY2C-targeting antibody drugs, and flow cytometry analysis of GUCY2C expression levels on colorectal cancer cell lines.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161
Product Information
Link：
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy 
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
Business license (three certificates in one) Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.
